Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

N.Y. Supplement Marketing Restriction Bill Raises Specter Of Copycats

This article was originally published in The Tan Sheet

Executive Summary

Stakeholders fear legislation proposed in New York to restrict sports supplement sales to consumers 18 and older and to require additional labeling could inspire copy-cats in other states. Trade groups say DSHEA already covers the proposed legislation’s goals.

You may also be interested in...



State Enforcement Needed On Weight Loss, Bodybuilding Supplements – Study

“The lax federal regulatory scheme for dietary supplements leaves extreme gaps in federal oversight that should be filled by state governments,” according to a report by public health experts. State attorneys general have “bully pulpit” to expand on enforcement authorities exercised by both FDA and FTC, they say.

State Enforcement Needed On Weight Loss, Bodybuilding Supplements – Study

“The lax federal regulatory scheme for dietary supplements leaves extreme gaps in federal oversight that should be filled by state governments,” according to a report by public health experts. State attorneys general have “bully pulpit” to expand on enforcement authorities exercised by both FDA and FTC, they say.

Hatch Flips Focus To NDI Guidance In McCain Steroid Bill Negotiations

In a bit of legislative jiu-jitsu, congressional dietary supplement champions have redirected Sen. John McCain from sponsoring a bill that would put new burdens on industry to backing a provision that requires FDA publish a guidance stakeholders have been pushing for

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106421

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel